ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS GLYCOPROTEIN 160 AS A VACCINE CANDIDATE FOR B CELL EPITOPE OF ACQUIRED IMMUNODEFICIENCY SYNDROME

Yani Suryani
10.14203/beritabiologi.v21i2.4295
| Abstract views: 287

Abstract

An in silico study was conducted to analyze the potential of Human Immunodeficiency Virus (HIV) glycoprotein 160 as a candidate source of B cell subunit (epitope) vaccine for Acquired Immunodeficiency Syndrome (AIDS). The method used was immunoinformatics. The tools used were a set of laptop device, uniprot application, IEDB AR application and ToxinPred application. The materials used were glycoprotein sequences. The analysis results showed that there were 4 candidate peptides for B cell subunit (epitope) vaccines for AIDS, namely MRVMGIQ (Methionine, Arginine, Valine, Methionine, Glycine, Isoleucine, Glutamine, NMWKNNM (Asparagine, Methionine, Tryptophan, Lysine, Asparagine, Asparagine, Methionine), EIMGDIR (Glutamate, Isoleucine, Methionine, Glycine, Aspartic Acid, Isoleucine, and Arginine) and MWQRVGQ (Methionine, Tryptophan, Glutamine, Arginine, Valine, Glycine and Glutamine). All peptides are non-toxic so they are safe for the body

Keywords

AIDS; epitope; glycoprotein; HIV; in silico

References

Abinaya, R. V., and Viswanathan, P. 2021. Biotechnology-based therapeutic. British: ScienceDirect.

Deeks SG. (2006) Antiretroviral treatment of HIV infected adults. BMJ, 332:1489

Dewi, I. P., Pharmacy, F., and Jember, U. 2016. B-Cell Epitope Prediction of Mycobacterium tuberculosis Ag85A ANTIGEN. ICMHS, ISBN 978-6, 108–111.

Ellis, R. W., Rappuoli, R., and Ahmed, S. 2012. Technologies for making new vaccines. In Vaccines: Sixth Edition (Sixth Edit). Elsevier Inc. https://doi.org/10.1016/B978-1-4557-0090-5.00013-6

Gupta, S., Kapoor, P., Chaudhary, K., Gautam , A., Kumar, R., and Raghava, G. P. 2015. Peptide Toxicity Prediction. Switzerland: Springer.

Gupta, S., Kapoor, P., Chaudhary, K., Gautam, A., and Kumar, R. 2013. In Silico Approch for Predicting Toxicuty of Peptides and Protein. PLOS ONE, 1-10.

Hardisman, D. 2009. HIV/AIDS di Indonesia: Fenomena Gunung Es dan Peranan Pelayanan Kesehatan Primer. Kesmas National Public Health Journal, 3(5):236

Kyte, J., and Doolittle, R. F.1982. A Simple Method for Displaying The Hydropathic Character of a Protein. J. Mol. Biol, 105-132.

Pollara, J., Easterhoff, D., and Fouda, G. G. 2017. Lesson learned from human HIV vaccine trials. Wolter Klauwer Health, Inc, 216-221.

Li, B., Xianfang, Z., Chuancui, H. and Yunx-ia, C. 2015. Human papillomavirus Genome-Wide Identification of T-cell Epitopes for Peptide Vaccine Develop-ment Against Cervical Cancer: An Inte-gration of Computational Analysis and Experimental Assay. J Computation Biol, 22(10), 962–974.

Senam. 1999. Bahaya Infeksi HIV (human Immunodeficiency Virus) Beserta Alternatif Pemecahannya. Cakrawala Pendidikan, 36-41.

Srebreneca, A., and Milanda, T. (2021). Pengembangan Vaksin HIV sebagai upaya preventif Terhadap AIDS. Farmaka, 19, 119–131.

Suryani, Y., Taupiqurrohman, O., Yusuf, M., Subroto, T., and Nuswantara, S. 2019. Immunoinformatics Study on Early 4 Protein of Human Papillomavirus Type 16 for Cervical Cancer Vaccine Peptide Candidate. Jurnal Biodjati, 4(2), 252–262. https://doi.org/10.15575/biodjati.v4i2.5414.

DOI: https://doi.org/10.14203/beritabiologi.v21i2.4295

Refbacks

  • There are currently no refbacks.